- Conditions
- Melanoma, Cancer
- Interventions
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes
- Interventions
- Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
- Drug
- Lead sponsor
- Edwin Horwitz
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Xerostomia Following Radiotherapy
- Interventions
- Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2a, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 9
- States / cities
- Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Interventions
- DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
- Biological · Drug
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy
- Biological
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2006
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 7
- States / cities
- Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
- Conditions
- HIV Infections
- Interventions
- Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Durham, North Carolina
- Conditions
- Solid Cancers
- Interventions
- Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, filgrastim, recombinant interferon alfa, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hepatitis C
- Interventions
- CTS-1027, pegylated interferon, Ribavirin, Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
- Conditions
- Polycythemia Vera, Essential Thrombocythemia
- Interventions
- RG7388, Pegasys
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
- Interventions
- IFN-gamma
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus
- Interventions
- MEDI 545, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 13 more
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- Memory Disorders, Alzheimer's Disease
- Interventions
- Aricept, IFN-alpha2A
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Baltimore, Maryland
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Kidney Cancer
- Interventions
- recombinant interferon alfa, tretinoin liposome
- Biological · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Major Depressive Disorder
- Interventions
- Exercise, Health Education
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Hepatitis Delta
- Interventions
- Peginterferon Lambda
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland